Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Avid Bioservices Inc (NQ: CDMOP )

25.06 USD UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 25.06
Bid (Size) 16.34 (1)
Ask (Size) 25.08 (189)
Prev. Close 25.06
Today's Range 25.06 - 25.06
52wk Range 24.01 - 31.95
Shares Outstanding N/A
Dividend Yield 10.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma... 
From GlobeNewswire News Releases
Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock
From GlobeNewswire News Releases

Performance

YTD
-10.72%
-10.72%
1 Month
N/A
N/A
3 Month
-1.09%
-1.09%
6 Month
-9.37%
-9.37%
1 Year
+0.02%
+0.02%

More News

Read More
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
From GlobeNewswire News Releases
Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes
From GlobeNewswire News Releases
Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes
From GlobeNewswire News Releases
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments
From GlobeNewswire News Releases
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
From GlobeNewswire News Releases
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021
From GlobeNewswire News Releases
Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan
From GlobeNewswire News Releases
Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
From GlobeNewswire News Releases
Avid Bioservices Announces Closing of Public Offering of Common Stock
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.